Candel Therapeutics to Participate in Upcoming Investor Conferences in September
NEEDHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical...
immunotherapy
MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells
CHICAGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company...
Fresenius Leads New EASYGEN Consortium Aimed at Decentralizing CAR-T Cell Therapy and Improving Hospital Workflows
Physicians, researchers, and partner institutions across Europe aim to deliver innovative, personalized therapies more quickly Development project focused on a...
Astrin Biosciences Appoints MIT Cancer Researcher Dr. Forest White as Distinguished Scientist to Advance Application of Proteomics for Early Cancer Detection
ST. PAUL, Minn., Aug. 26, 2025 /PRNewswire/ -- Today, Astrin Biosciences, the cancer intelligence company transforming detection and treatment via...
Adagene to Participate in Two Investor Conferences in September
SAN DIEGO and SUZHOU, China, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company...
PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer
Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of...
24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets
Current Clinical Trial Focus is MSS Colorectal Cancer, Ovarian Clear-Cell Carcinoma, and Soft-Tissue SarcomaDENVER, Aug. 25, 2025 (GLOBE NEWSWIRE) --...
Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
Proprietary platform is built on one of the largest multimodal oncology datasets, including 250,000+ tumor exomes, 1 million+ plasma timepoints,...
Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
Proprietary platform is built on one of the largest multimodal oncology datasets, including 250,000+ tumor exomes, 1 million+ plasma timepoints,...
TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
TAMPA, Fla., Aug. 20, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel therapeutics to...
REPEAT — Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) --...
LIXTE Biotechnology Holdings Provides Corporate Update
-Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board...
OncoC4 Strengthens Leadership Team with Appointment of Shiniu Wei as Chief Financial Officer
ROCKVILLE, Md., Aug. 18, 2025 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer today...
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
ENX-CL-05-001 Trial: 3-months topline data - In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including...
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business UpdatesEntered into a definitive...
Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market
SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight...
Invitation to the presentation of ALK’s first six months (Q2) 2025 results on Thursday, 21 August 2025
ALK (ALKB.DC / OMX: ALK B) will publish its results for the first six months of 2025 in the morning...
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
BOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar
Webinar to Review Results from Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Allocetra™ in Patients with Moderate to Severe Knee Osteoarthritis...
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025
Breakthrough Epigenetic Modulator LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon CancerDENVER, Aug. 14,...